Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania

Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With 
GeneKor to Include Turkey and Romania 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 11/20/13 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces the
expansion of its distribution agreement with GeneKor Medical S.A for
the exclusive sales and marketing of the Company's suite of
microRNA-based cancer testing services in Romania and non-exclusive
distribution in Turkey, in addition to the original agreement
covering Greece. GeneKor is a leading molecular diagnostic service
provider based in Greece. 
"We are delighted to expand our relationship with GeneKor, a leading
molecular diagnostics company with experience in distributing
high-complexity oncology tests. We look forward to building upon our
established relationship to leverage the need for better cancer
diagnostics with Rosetta's powerful microRNA-based product
portfolio," stated Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. "Developments in targeted cancer
therapies are driving the need for more accurate classification of
tumor types to guide treatment decisions. Our microRNA technologies,
with their high reproducibility, robustness and accuracy, are well
suited to provide valuable clinical information to predict and
diagnose cancer, and therefore to help optimize treatment." 
E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical
Officer, said: "This extension to our agreement with Genekor will
enhance patient access to our microRNA-based testing services in
Turkey and Romania, and will potentially result in more personalized
treatment approaches for many patients. In addition, this new
agreement underscores our commitment to expand personalized medicine
across the globe, and to help improve patient outcomes." 
About Rosetta Cancer Testing Services 
 Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data;
it is the treating physician's responsibility to diagnose and
administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the
Rosetta Cancer Origin Test(TM), 60,000 from the Rosetta Mesothelioma
Test(TM), 65,000 from the Rosetta Kidney Cancer Test(TM) and 226,000
patients from the Rosetta Lung Cancer Test(TM). The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. For more information, please visit Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309. 
About GeneKor
 GeneKor Medical S.A. was founded in 2007 and operates
molecular biology laboratories with state-of-the-art equipment
suitable to provide the highest quality services. GeneKor provides a
diversification of services focused on improving patient care
utilizing the latest technologies of prognostic, predictive and
personalized medicine.  As of June 2012, the specialized laboratory
of GeneKor  has been accredited by ISO 15189:2007 for Clinical
Laboratories by the Hellenic Accreditation System S.A.
(Ε.ΣΥ.Δ.), while it has also been certified by
International quality Standards Organizations (ISO 9001:2008), from
independent international certification bodies (TUV Nord). GeneKor
services are assured through External Quality Assurance by the
European Molecular Genetics Quality Network (EMQN), the National
External Quality Assessment Service (UK NEQAS) and the College of
American Pathologist (CAP).  GeneKor. is staffed by board-certified
internationally recognized and published scientists and doctors who
are able to provide analyses and recommendations to physicians and
their patients. As such, GeneKor. is in position to carry out all
existing molecular biology assays. GeneKor offers treating physicians
various tools to individualize patient treatment.  GeneKor is devoted
to offering the highest-quality services by constantly monitoring
scientific developments in the health sector, updating its laboratory
equipment and maximizing its levels of accuracy and reliability.
GeneKor is also operating in Romania and Turkey and actively
establishing its international presence with an ultimate goal of
extending its collaborations in more countries. GeneKor's strategic
goal is the constant incorporation of new technology platforms and
assays in order to consistently provide the most up-to-date, reliable
and cutting-edge tools to the treating physicians. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test(TM), Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test(TM), Rosetta's
development of personalized medicine products and services, Rosetta
licensing, partnering, entering into distribution agreements or
otherwise deriving value from microRNA technology for use in a
variety of diagnostic and targeted therapeutics and Rosetta
developing therapeutic products, the reproducibility, robustness and
accuracy of Rosetta's microRNA technology and its ability to help
optimize treatment and the extension of the agreement with Genekor
enhancing patient access to Rosetta testing services in Romania and
Turkey, constitute forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including those risks more fully discussed in the
"Risk Factors" section of Rosetta's Annual Report on Form 20-F for
the year ended December 31, 2012 as filed with the SEC. In addition,
any forward-looking statements represent Rosetta's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless
required by law. 
Company Contact:
Rosetta Genomics
Ken Berlin
President & CEO
(609) 419-9000, ext. 1326 
Investor Contacts:
Anne Marie Fields
(212) 838-3777 
Bruce Voss
(310) 691-7100 
Press spacebar to pause and continue. Press esc to stop.